^
Association details:
| Biomarker: | KRAS G12C + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Immunotherapy in patients with lung cancer with driver mutations: A single center experience.
Published date:
05/19/2021
Excerpt:
We found MET exon 14 skip mutation in 2 and RAS in 2 patients. Immunotherapy combined with chemotherapy was given in 5(50%) patients...Single agent checkpoint inhibitors seem to have a limited impact in treatment in patients with driver mutations....We do see benefit in patients who received PD1/PDL1 inhibitors in combination with chemotherapy with/ without Bevacizumab.
Secondary therapy:
Chemotherapy
DOI:
10.1200/JCO.2021.39.15_suppl.e21170
